AC Immune KOL Webinar on First Clinical Proof of Concept for Alpha-synuclein Diagnostic Shows Breakthrough Potential for Neurodegenerative diseases
a-syn PET tracer, ACI-12589, clinically validated in MSA, potentially enables accelerated development of targeted therapeutics and additional a-syn diagnostics
Another first for validated Morphomer® discovery technology platform in developing small molecules able to selectively target pathological human proteins
AC Immune pipeline includes a-syn diagnostic and multiple a-syn therapeutic candidates
AC Immune on track to deliver seven clinical data readouts in 2022
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, hosted leading research scientist and key opinion leader Dr. Oskar Hansson for a webinar focused on a-synuclein as a diagnostic and therapeutic target in neurodegenerative diseases. AC Immune and Dr Hansson reported at the recent AD/PD™ conference, data showing that AC Immune’s wholly owned a-syn PET tracer ACI-12589 was the first-ever radiotracer to distinguish multiple system atrophy (MSA) from other a-synucleinopathies, i.e. Parkinson’s disease (PD) and Lewy body dementia (LBD), and healthy volunteers.